| 3 0.01 (0.33%) | 01-26 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.54 | 1-year : | 10.51 |
| Resists | First : | 6.46 | Second : | 9 |
| Pivot price | 4.14  |
|||
| Supports | First : | 2.35 | Second : | 1.96 |
| MAs | MA(5) : | 2.98  |
MA(20) : | 4.6 |
| MA(100) : | 9.9 |
MA(250) : | 10.79 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 15.2 |
| RSI | RSI(14): 30.9 |
|||
| 52-week | High : | 46.5 | Low : | 2.35 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CODX ] has closed above bottom band by 31.0%. Bollinger Bands are 26.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.23 |
| Low: | 2.9 - 2.91 | 2.91 - 2.93 |
| Close: | 2.97 - 3 | 3 - 3.02 |
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Fri, 23 Jan 2026
Co-Diagnostics (CODX) Downgraded to Hold by Maxim Group Today | - GuruFocus
Tue, 13 Jan 2026
Co-Diagnostics Received Notice of Delisting - TradingView
Tue, 13 Jan 2026
Co-Diagnostics to be delisted from Nasdaq, trading to move to OTC Market - Investing.com
Mon, 12 Jan 2026
Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships - PR Newswire
Mon, 12 Jan 2026
Lab conferences boost CoSara's India network for future TB PCR tests - Stock Titan
Tue, 30 Dec 2025
Co-Diagnostics Announces Reverse Stock Split - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.8e+006 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.433e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 824.4 % |
| Return on Equity (ttm) | -38 % |
| Qtrly Rev. Growth | 507890 % |
| Gross Profit (p.s.) | -61.35 |
| Sales Per Share | -49.31 |
| EBITDA (p.s.) | 137175 |
| Qtrly Earnings Growth | -29.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.07 |
| Price to Cash Flow | 0.15 |
| Dividend | 0 |
| Forward Dividend | 75070 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|